Drugs / VERUCERFONT
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT02349503 | Feb → Oct 2015 | classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency | Neurocrine Biosciences | Withdrawn | No outcome recorded |
| Phase 1 | NCT00539136 | Oct 2007 → Mar 2008 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00513565 | Sep 2007 → May 2009 | mixed anxiety and depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00555139 | Mar 2007 → Jan 2008 | social phobia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00426608 | Oct 2006 → Jan 2007 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 24 trials · 2 missed | ||||||
| Phase 2 | NCT01814332 | Jan 2010 → Jun 2014 | post-traumatic stress disorder | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 2 | NCT01018992 | Dec 2009 → Aug 2014 | post-traumatic stress disorder | Emory University | Completed | Missed primary |
| Phase 2 | NCT00733980 | Oct 2008 → Jun 2010 | major depressive disorder | GlaxoSmithKline | Completed | Missed primary |
| Phase 2 | NCT00511563 | Aug 2007 → Nov 2012 | irritable bowel syndrome | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01187511 Comparator | Jan 2010 → Sep 2015 | alcohol dependence | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2015-01-16 | Neurocrine Biosciences | Regulatory Neurocrine Biosciences Announces Granting of Orphan Drug Status for NBI-77860 in Congenital Adrenal Hyperplasia gcs-web.com ↗
We are very pleased that the FDA has granted NBI-77860 orphan status to treat congenital adrenal hyperplasia, a devastating disease that is a significant challenge for both clinicians and patients, |
| 2014-12-10 | Neurocrine Biosciences | Results Neurocrine Biosciences Announces Expansion of its Clinical Pipeline gcs-web.com ↗
Initial Pilot Clinical Study Demonstrated Profound Impact on Key Biomarkers |
| 2010-09-14 | Neurocrine Biosciences | Results Neurocrine Announces Top-Line Results of Corticotropin Releasing Factor Antagonist GSK561679 for Treatment of Major Depressive Disorder gcs-web.com ↗
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced top-line efficacy and safety results from a Phase II clinical trial utilizing Corticotropin Releasing Factor (CRF1) receptor antagonist GSK561679 in patients currently experiencing a major depressive episode. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2015-01-20 | Neurocrine Biosciences | Neurocrine Biosciences Announces Oral Presentation of NBI-77860 Clinical Trial Data in Classic Congenital Adrenal Hyperplasia at ENDO 2015 gcs-web.com ↗ |
| 2015-01-16 | Neurocrine Biosciences | Neurocrine Biosciences Announces Granting of Orphan Drug Status for NBI-77860 in Congenital Adrenal Hyperplasia gcs-web.com ↗ |
| 2014-12-10 | Neurocrine Biosciences | Neurocrine Biosciences Announces Expansion of its Clinical Pipeline gcs-web.com ↗ |
| 2010-09-14 | Neurocrine Biosciences | Neurocrine Announces Top-Line Results of Corticotropin Releasing Factor Antagonist GSK561679 for Treatment of Major Depressive Disorder gcs-web.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VERUCERFONT | ChEMBL registry synonym — accepted as the source's own label CHEMBL1287935 ↗ |
| Known as | GSK-561679A | ChEMBL registry synonym — accepted as the source's own label CHEMBL1287935 ↗ |
| Known as | GSK561679 | “Subjects will receive single doses of GSK561679, lorazepam, or placebo at each treatment session.” NCT00513565 ↗ |
| Known as | NBI-77860 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02349503 ↗ |
| Action | Inhibit | “Two CRF-1 antagonists GSK561679 and GW876008” NCT00511563 ↗ |
| Modality | Small molecule | — CHEMBL1287935 ↗ |
| Route | Oral | “GSK561679, oral administration, 350mg/day, 6 week administration” NCT01018992 ↗ |
| Target | CRHR1 | “GSK561679, a novel CRHR1 receptor antagonist” PMID 24950747 ↗ Jun 2014 |